Nina Beri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nina Beri has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Andressa Dias Costa
Dana-Farber Cancer Institute 1 Department of Medical Oncology Harvard Medical School, Boston, Massachusetts
31 shared publications - Benjamin L. Schlechter
Dana-Farber Cancer Institute 1 , Boston, Massachusetts
31 shared publications - Brandon M. Huffman
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
31 shared publications - Brian M. Wolpin
Dana-Farber Cancer Institute, Boston, MA
31 shared publications - C. Elizabeth Keheler
Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts. 8
31 shared publications - Cibelle Lima
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 3
31 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 3: Presence of canakinumab does not interfere with the ability to detect IL-1b in patient serum. Baseline serum from three randomly selected patients with pancreatic ductal adenocarcinoma was evaluated by cytokine bead array for IL-1b. For each patient sample, canakinumab was spiked in at the indicated concentrations. Note that measured IL-1b values were consistent across all samples from the same patient, regardless of the presence of canakinumab.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 3: Presence of canakinumab does not interfere with the ability to detect IL-1b in patient serum. Baseline serum from three randomly selected patients with pancreatic ductal adenocarcinoma was evaluated by cytokine bead array for IL-1b. For each patient sample, canakinumab was spiked in at the indicated concentrations. Note that measured IL-1b values were consistent across all samples from the same patient, regardless of the presence of canakinumab.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 6. Cell populations identified by transcriptional profiling from tumor biopsies. (A) UMAP of all cells in the dataset, colored by cluster. (B-C) Relative expression of representative genes of the six major compartments across the full dataset. (D) Relative expression of IL1B, IL1R1, PDCD1, PDCDLG1, and PDCDLG2 across the full dataset. (E) The percent of each myeloid cluster that is found in each of the samples, separated into baseline and treated subgroups (Wilcoxon rank-sum test).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 6. Cell populations identified by transcriptional profiling from tumor biopsies. (A) UMAP of all cells in the dataset, colored by cluster. (B-C) Relative expression of representative genes of the six major compartments across the full dataset. (D) Relative expression of IL1B, IL1R1, PDCD1, PDCDLG1, and PDCDLG2 across the full dataset. (E) The percent of each myeloid cluster that is found in each of the samples, separated into baseline and treated subgroups (Wilcoxon rank-sum test).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 7: Macrophage subtypes are unaffected by treatment in patients in SR-1. (A) Baseline and on-treatment biopsies from patients (n = 6 paired samples) in the SR-1 trial were analyzed by multiplex immunofluorescence using the indicated antibodies. Representative image of the macrophage panel is shown. (B) Densities of total macrophages (CD68+ or CD163+ cells). (C) Densities of M1 polarized macrophages (CD86+IRF5+). (D) Densities of M2 polarized macrophages (CD206+CD163+).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 7: Macrophage subtypes are unaffected by treatment in patients in SR-1. (A) Baseline and on-treatment biopsies from patients (n = 6 paired samples) in the SR-1 trial were analyzed by multiplex immunofluorescence using the indicated antibodies. Representative image of the macrophage panel is shown. (B) Densities of total macrophages (CD68+ or CD163+ cells). (C) Densities of M1 polarized macrophages (CD86+IRF5+). (D) Densities of M2 polarized macrophages (CD206+CD163+).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 2: Pharmacokinetics of canakinumab. Serum levels of canakinumab were measured in patients on SR-1 at the indicated time points.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 2: Pharmacokinetics of canakinumab. Serum levels of canakinumab were measured in patients on SR-1 at the indicated time points.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 1: Progression-free survival for SR-1, an open-label multicenter phase Ib study evaluating gemcitabine, n(ab)-paclitaxel, canakinumab and spartalizumab in advanced pancreatic ductal adenocarcinoma. A) PFS for the 10 patients in SR-1 is shown. B) OS for the 10 patients in SR-1 is shown. C) PFS for the 11 patients in the GnP cohort is shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 1: Progression-free survival for SR-1, an open-label multicenter phase Ib study evaluating gemcitabine, n(ab)-paclitaxel, canakinumab and spartalizumab in advanced pancreatic ductal adenocarcinoma. A) PFS for the 10 patients in SR-1 is shown. B) OS for the 10 patients in SR-1 is shown. C) PFS for the 11 patients in the GnP cohort is shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 2: Patient sample information and types of experimental data collected from each patient.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 2: Patient sample information and types of experimental data collected from each patient.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 3: Serum samples from baseline and on-treatment time points from patients in SR-1, the standard of care cohort, and healthy people who donated blood 28 days apart were analyzed by cytokine bead array. Significance was determined by Wilcoxon matched-pairs signed rank test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 3: Serum samples from baseline and on-treatment time points from patients in SR-1, the standard of care cohort, and healthy people who donated blood 28 days apart were analyzed by cytokine bead array. Significance was determined by Wilcoxon matched-pairs signed rank test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 1: Selected Adverse Events reported in ≥5 subjects (any grade) or ≥3 subjects for Grade 3 from patients in SR-1. Select immune-related adverse events are also shown.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Table 1: Selected Adverse Events reported in ≥5 subjects (any grade) or ≥3 subjects for Grade 3 from patients in SR-1. Select immune-related adverse events are also shown.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 5: Addition of TNFa ameliorates myeloid suppression in vitro. (A) Histogram of HLA-DR mean fluorescence intensity of CD33+ SSCA high cells from monocytes cocultured for a week with 75 pg/ML M-CSF with the addition of 10 ng/mL each GM-CSF/ IL-6 or 10ng/mL IL-1b with or without an IL-1b blocking antibody. (B) Induced MoMDSCs from panel A were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Proliferation indices were calculated. (C) MoMDSCs induced from monocytes cultured for 7 days with the indicated cytokines were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Representative histograms are shown. (D) Proliferation indices from the data shown in C were calculated.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 5: Addition of TNFa ameliorates myeloid suppression in vitro. (A) Histogram of HLA-DR mean fluorescence intensity of CD33+ SSCA high cells from monocytes cocultured for a week with 75 pg/ML M-CSF with the addition of 10 ng/mL each GM-CSF/ IL-6 or 10ng/mL IL-1b with or without an IL-1b blocking antibody. (B) Induced MoMDSCs from panel A were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Proliferation indices were calculated. (C) MoMDSCs induced from monocytes cultured for 7 days with the indicated cytokines were then cultured with CFSE-labeled T cells for 3 days coculture at a 1:1 ratio, and T cell proliferation was assessed by flow cytometry. Representative histograms are shown. (D) Proliferation indices from the data shown in C were calculated.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 4: Flow cytometry gating strategy for the PBMC samples shown in Figures 2 and 3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Supplemental Figure 4: Flow cytometry gating strategy for the PBMC samples shown in Figures 2 and 3.